Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$205.12 +1.2%	$196.83	$153.58 ▼ $218.66	$362.85B	0.61	5.70 million shs	4.87 million shs
IQV IQVIA	$177.27 -1.2%	$193.55	$176.03 ▼ $253.84	$31.25B	1.5	1.46 million shs	1.38 million shs
JNJ Johnson & Johnson	$163.63 +0.3%	$158.35	$140.68 ▼ $169.99	$394.32B	0.47	7.62 million shs	4.09 million shs
NVS Novartis	$112.69 +1.2%	$107.62	$92.35 ▼ $120.92	$230.34B	0.53	2.21 million shs	2.37 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.81%	-4.13%	-0.68%	+13.92%	+12.44%
IQV IQVIA	-0.28%	-2.57%	-6.06%	-10.03%	-28.97%
JNJ Johnson & Johnson	+0.97%	+0.18%	-1.75%	+12.52%	+3.33%
NVS Novartis	+1.25%	-1.67%	+1.58%	+13.28%	+16.25%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.5553 of 5 stars	2.5	3.0	3.3	3.9	3.5	2.5	1.3
IQV IQVIA	4.7292 of 5 stars	4.4	3.0	0.0	4.6	3.0	1.7	1.3
JNJ Johnson & Johnson	4.4395 of 5 stars	2.3	3.0	4.2	3.9	3.5	2.5	0.6
NVS Novartis	3.0286 of 5 stars	1.9	5.0	2.5	0.0	3.4	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	3.09% Upside
IQV IQVIA	2.86	Moderate Buy	$249.05	40.50% Upside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	4.71% Upside
NVS Novartis	1.80	Reduce	$123.38	9.48% Upside

Current Analyst Ratings Breakdown

Latest NVS, ABBV, JNJ, and IQV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/17/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/5/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$159.00 ➝ $171.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00
3/4/2025	IQV IQVIA	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$225.00 ➝ $210.00
2/19/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
2/18/2025	IQV IQVIA	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$240.00 ➝ $232.00
2/13/2025	NVS Novartis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/12/2025	NVS Novartis	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight
2/11/2025	IQV IQVIA	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$245.00 ➝ $250.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.44	$15.16 per share	13.53	$1.90 per share	107.96
IQV IQVIA	$15.41B	2.03	$15.18 per share	11.68	$34.45 per share	5.15
JNJ Johnson & Johnson	$88.82B	4.44	$13.45 per share	12.17	$29.69 per share	5.51
NVS Novartis	$51.72B	4.45	$11.24 per share	10.03	$21.59 per share	5.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	85.47	14.67	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
IQV IQVIA	$1.37B	$7.50	23.64	14.53	1.99	8.91%	28.81%	7.02%	5/1/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.61	14.78	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
NVS Novartis	$11.94B	$5.88	19.17	12.79	1.70	23.56%	37.24%	15.85%	4/29/2025 (Estimated)

Latest NVS, ABBV, JNJ, and IQV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/25/2025	N/A	ABBV AbbVie	$2.51	N/A	N/A	N/A	$12.91 billion	N/A
4/22/2025	N/A	NVS Novartis	$2.07	N/A	N/A	N/A	N/A	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/6/2025	Q4 2024	IQV IQVIA	$3.11	$2.90	-$0.21	$2.42	N/A	N/A
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A
1/31/2025	Q4 2024	NVS Novartis	$1.80	$1.98	+$0.18	$1.41	$12.86 billion	N/A
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.20%	+6.04%	273.33%	53 Years
IQV IQVIA	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.03%	+5.43%	74.59%	63 Years
NVS Novartis	$2.51	2.23%	+5.34%	42.69%	N/A

Latest NVS, ABBV, JNJ, and IQV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
2/20/2025	NVS Novartis		$3.8695		3/12/2025	3/12/2025	3/12/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
IQV IQVIA	2.12	0.84	0.84
JNJ Johnson & Johnson	0.43	1.11	0.86
NVS Novartis	0.48	1.04	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
IQV IQVIA	89.62%
JNJ Johnson & Johnson	69.55%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
IQV IQVIA	1.60%
JNJ Johnson & Johnson	0.16%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
IQV IQVIA	86,000	176.32 million	173.28 million	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
NVS Novartis	101,700	2.04 billion	2.04 billion	Optionable

NVS, ABBV, JNJ, and IQV Headlines

Recent News About These Companies

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto

March 28 at 3:39 PM | appliedclinicaltrialsonline.com

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

March 28 at 12:52 PM | globenewswire.com

Here's Why Novartis (NVS) is a Strong Value Stock

March 28 at 10:40 AM | zacks.com

Novartis AG (NYSE:NVS) Shares Sold by Loomis Sayles & Co. L P

March 28 at 6:48 AM | marketbeat.com

Proficio Capital Partners LLC Buys Shares of 2,312 Novartis AG (NYSE:NVS)

March 28 at 3:20 AM | marketbeat.com

Congress Wealth Management LLC DE Sells 22,499 Shares of Novartis AG (NYSE:NVS)

March 27 at 4:48 AM | marketbeat.com

Wambolt & Associates LLC Has $2.59 Million Holdings in Novartis AG (NYSE:NVS)

March 26 at 7:44 AM | marketbeat.com

Novartis put volume heavy and directionally bearish

March 26 at 6:34 AM | markets.businessinsider.com

CoreFirst Bank & Trust Buys Shares of 2,310 Novartis AG (NYSE:NVS)

March 26 at 5:32 AM | marketbeat.com

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

March 25 at 9:39 AM | pmlive.com

5 Large Drug Stocks to Watch as Industry Recovers

March 25 at 7:50 AM | zacks.com

Mill Capital Management LLC Cuts Stock Position in Novartis AG (NYSE:NVS)

March 25 at 5:54 AM | marketbeat.com

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

March 25 at 2:15 AM | globenewswire.com

Chinese VP meets Swire Pacific Limited chairman, Novartis CEO

March 24, 2025 | chinaview.cn

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

March 24, 2025 | zacks.com

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

March 24, 2025 | zacks.com

Sei Investments Co. Buys 16,519 Shares of Novartis AG (NYSE:NVS)

March 24, 2025 | marketbeat.com

Virtu Financial LLC Has $1 Million Stake in Novartis AG (NYSE:NVS)

March 24, 2025 | marketbeat.com

Marietta Investment Partners LLC Has $1.73 Million Stock Position in Novartis AG (NYSE:NVS)

March 23, 2025 | marketbeat.com

36,154 Shares in Novartis AG (NYSE:NVS) Bought by Summit Global Investments

March 23, 2025 | marketbeat.com

Millstone Evans Group LLC Acquires Shares of 3,132 Novartis AG (NYSE:NVS)

March 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Volatility Is Back: 3 Stocks To Cushion the S&P 500's Swings
By Gabriel Osorio-Mazilli | February 27, 2025
View Volatility Is Back: 3 Stocks To Cushion the S&P 500's Swings
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
By Chris Markoch | March 23, 2025
View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility

NVS, ABBV, JNJ, and IQV Company Descriptions

AbbVie NYSE:ABBV

$205.12 +2.40 (+1.18%)

Closing price 03:59 PM Eastern

Extended Trading

$205.23 +0.11 (+0.05%)

As of 04:10 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

IQVIA NYSE:IQV

$177.26 -2.10 (-1.17%)

Closing price 03:59 PM Eastern

Extended Trading

$177.34 +0.08 (+0.04%)

As of 04:05 PM Eastern

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Johnson & Johnson NYSE:JNJ

$163.63 +0.50 (+0.31%)

Closing price 03:59 PM Eastern

Extended Trading

$163.35 -0.28 (-0.17%)

As of 04:11 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novartis NYSE:NVS

$112.69 +1.29 (+1.16%)

Closing price 03:59 PM Eastern

Extended Trading

$112.57 -0.12 (-0.11%)

As of 04:05 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time